X

Trial Profile

Trial of CTX 1301 (Dexmethylphenidate) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 16 Jan 2018

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dexmethylphenidate (Primary)
Indications Attention-deficit hyperactivity disorder
Focus First in man; Pharmacokinetics; Proof of concept

Most Recent Events

16 Jan 2018 According to a Cingulate Therapeutics media release, results from this trial were presented at the 2018 American Professional Society of ADHD and Related Disorders (APSARD) Annual Meeting.
15 Jan 2018 Results presented in a Cingulate Therapeutics media release.
10 Jul 2017 Status changed from recruiting to completed, according to a Cingulate Therapeutics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com